[go: up one dir, main page]

MX2011008336A - Derivados de dihidroquinolinona. - Google Patents

Derivados de dihidroquinolinona.

Info

Publication number
MX2011008336A
MX2011008336A MX2011008336A MX2011008336A MX2011008336A MX 2011008336 A MX2011008336 A MX 2011008336A MX 2011008336 A MX2011008336 A MX 2011008336A MX 2011008336 A MX2011008336 A MX 2011008336A MX 2011008336 A MX2011008336 A MX 2011008336A
Authority
MX
Mexico
Prior art keywords
formula
dihydroquinolinone
disorders
sleep
narcolepsy
Prior art date
Application number
MX2011008336A
Other languages
English (en)
Inventor
Toshio Nakamura
Seiji Masuda
Aya Futamura
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of MX2011008336A publication Critical patent/MX2011008336A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención provee un agente profiláctico o terapéutico para demencia, enfermedad de Alzheimer, trastorno de hiperactividad y déficit de atención, esquizofrenia, trastornos de alimentación, obesidad, diabetes, hiperlipidemia, trastornos del sueño, narcolepsia, síndrome de apnea de sueño, trastorno del ritmo circadiano, depresión, rinitis alérgica u otras enfermedades; un derivado de dihidroquinolinona representado por la fórmula (1) o una sal aceptable para uso farmacéutico del mismo: (ver fórmula (1)) en la que Q representa la siguiente fórmula (A) o (B) (ver fórmula (2).
MX2011008336A 2009-02-06 2010-02-05 Derivados de dihidroquinolinona. MX2011008336A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009025462 2009-02-06
JP2009146735 2009-06-19
PCT/JP2010/052114 WO2010090347A1 (en) 2009-02-06 2010-02-05 Dihydroquinolinone derivatives

Publications (1)

Publication Number Publication Date
MX2011008336A true MX2011008336A (es) 2011-08-24

Family

ID=42026194

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008336A MX2011008336A (es) 2009-02-06 2010-02-05 Derivados de dihidroquinolinona.

Country Status (16)

Country Link
US (1) US8609847B2 (es)
EP (1) EP2393802B1 (es)
JP (1) JP5678889B2 (es)
KR (1) KR20110113734A (es)
CN (1) CN102307867A (es)
AR (1) AR075229A1 (es)
AU (1) AU2010211583A1 (es)
BR (1) BRPI1007369A2 (es)
CA (1) CA2750714A1 (es)
IL (1) IL214293A0 (es)
MX (1) MX2011008336A (es)
RU (1) RU2011136821A (es)
SG (1) SG173555A1 (es)
TW (1) TW201039822A (es)
WO (1) WO2010090347A1 (es)
ZA (1) ZA201105014B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
JP6218366B2 (ja) * 2012-09-04 2017-10-25 大正製薬株式会社 H3受容体の放射性標識リガンド
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
IN2014MU00197A (es) * 2014-01-21 2015-08-28 Wanbury Ltd
US9145388B2 (en) 2014-02-19 2015-09-29 King Fahd University Of Petroleum And Minerals 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones
CN104130187B (zh) * 2014-05-27 2017-02-15 浙江工业大学 一种手性二氢喹啉酮类化合物的不对称合成方法
US10428030B2 (en) * 2015-10-30 2019-10-01 Trillium Therapeutics Heterocycle derivatives and their use for the treatment of CNS disorders
CN110156676B (zh) * 2019-06-26 2020-11-03 绍兴文理学院 一种3,4-二氢喹啉-2(1h)-酮类衍生物及其制备方法与应用
CN113024435B (zh) * 2019-12-09 2022-06-17 苏州恩华生物医药科技有限公司 连双环结构sigma-1受体抑制剂
CN115784983B (zh) * 2022-12-05 2024-09-27 井冈山大学 6-胺烷氧基-3,4-二氢喹啉酮衍生物及制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62135423A (ja) 1985-12-09 1987-06-18 Otsuka Pharmaceut Co Ltd 低酸素症改善剤
DK588486A (da) 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
KR940000785B1 (ko) 1986-04-02 1994-01-31 오오쓰까세이야꾸 가부시끼가이샤 카르보스티릴 유도체 및 그의 염의 제조 방법
DK167187A (da) 1986-04-02 1987-10-03 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
JPH0681727B2 (ja) 1986-04-02 1994-10-19 大塚製薬株式会社 血小板粘着抑制剤
JPS63290821A (ja) 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd 抗不整脈剤
TW448161B (en) * 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
US20060167046A1 (en) * 2002-09-18 2006-07-27 Eli Lilly And Company Patent Division Histamine h3 receptor antagonists, preparation and therapeutic uses
RU2358969C2 (ru) * 2004-02-13 2009-06-20 Баниу Фармасьютикал Ко., Лтд. Конденсированное 4-оксопиримидиновое производное
CA2561791A1 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds
GB0408083D0 (en) * 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
ATE472540T1 (de) 2004-05-07 2010-07-15 Warner Lambert Co Als h3-liganden geeignete 3- oder 4- monosubstituierte phenol- und thiophenol-derivate
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
AU2005299018B2 (en) 2004-10-19 2011-07-07 F. Hoffmann-La Roche Ag Quinoline derivatives
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
CA2588867A1 (en) 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. Substituted pyridone derivative
WO2006061193A1 (en) 2004-12-07 2006-06-15 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
CA2602336A1 (en) 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
EP1868991B1 (en) 2005-04-01 2014-07-30 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JP2007001944A (ja) * 2005-06-24 2007-01-11 Sankyo Agro Kk 3,4−ジヒドロ−1,3’−ビキノリン−2−オン誘導体

Also Published As

Publication number Publication date
SG173555A1 (en) 2011-09-29
ZA201105014B (en) 2012-09-26
JP5678889B2 (ja) 2015-03-04
US8609847B2 (en) 2013-12-17
TW201039822A (en) 2010-11-16
JP2012517400A (ja) 2012-08-02
AR075229A1 (es) 2011-03-16
US20120022064A1 (en) 2012-01-26
RU2011136821A (ru) 2013-03-20
BRPI1007369A2 (pt) 2018-06-12
CN102307867A (zh) 2012-01-04
EP2393802A1 (en) 2011-12-14
AU2010211583A1 (en) 2011-09-01
KR20110113734A (ko) 2011-10-18
EP2393802B1 (en) 2013-05-08
IL214293A0 (en) 2011-09-27
CA2750714A1 (en) 2010-08-12
WO2010090347A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
MX2011008336A (es) Derivados de dihidroquinolinona.
CY1121543T1 (el) Ενωση πυριδυλαμινοοξεικου οξεος
PH12012501917A1 (en) Phenylpyrazole derivatives
NZ589764A (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
MX2011011489A (es) Derivados de isoxazol-piridina.
TW201144302A (en) 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
NZ617334A (en) Cyclopropyl amine derivatives
GEP20115176B (en) Prodrug of cinnamide compound
JP2011148799A5 (es)
MX2011011273A (es) Derivados de isoxazol-pirazol.
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
NO20075086L (no) Behandling av Parkinsons sykdom, obstruktiv sovn apne, demens med Lewy legemer, vaskulaer demens med ikke-imidazol alkylamin histamin H3-reseptor ligander
WO2007048801A3 (en) Sexual desire enhancing medicaments comprising benzimidazolone derivatives
IL179906A0 (en) Novel hydantoin derivatives for the treatment of obstructive airway diseases
TN2012000092A1 (en) Therapeutic agent for mood disorders
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MX2010001352A (es) Derivados de n-(2-tiazolil)-amida para el tratamiento de obesidad, diabetes y enfermedades cardiovasculares.
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
WO2007039462A3 (en) Indane derivatives as mch receptor antagonists
PH12014501293A1 (en) Phenylpyrrole derivative
TN2012000093A1 (en) Therapeutic agent for anxiety disorders
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
MX2007010400A (es) Nuevas sales de derivados de hexahidrofenantridina sustituida con 6-heterociclilo.

Legal Events

Date Code Title Description
FG Grant or registration